GALT
GALT
NASDAQ · Biotechnology

Galectin Therapeutics Inc

$2.68
-0.12 (-4.29%)
As of Mar 29, 10:36 PM ET ·
Financial Highlights (FY 2025)
Revenue
42.71M
Net Income
-4,071,906
Gross Margin
53.3%
Profit Margin
-9.5%
Rev Growth
+12.9%
D/E Ratio
0.88
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 53.3% 53.3% 53.3%
Operating Margin -9.8% -9.9% -11.3%
Profit Margin -9.5% -11.4% -10.2%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 42.71M 37.98M 43.70M
Gross Profit 22.78M 20.26M 23.31M
Operating Income -4,164,747 -3,762,219 -4,921,777
Net Income -4,071,906 -4,331,190 -4,441,576
Gross Margin 53.3% 53.3% 53.3%
Operating Margin -9.8% -9.9% -11.3%
Profit Margin -9.5% -11.4% -10.2%
Rev Growth +12.9% +2.3% +21.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 74.62M 82.00M 80.44M
Total Equity 85.11M 74.58M 75.96M
D/E Ratio 0.88 1.10 1.06
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -6,278,520 -5,337,134 -5,924,921
Free Cash Flow -4,174,488 -3,744,064 -5,531,991